Treatment of Synovial Sarcoma in Patients Younger Than 18 Years

Synovial sarcoma occurring in pediatric patients presents specific management considerations. This page summarises the first-line approach for patients under 18 years of age, where evidence from dedicated prospective studies and joint cooperative-group analyses has helped define an optimal framework.

Clinical Scenario

Pediatric synovial sarcoma (age <18 years) is rare, making it inherently difficult to conduct large randomised trials in this specific population. Despite this, the optimal treatment approach for these patients is now better defined, drawing on prospective pediatric and adolescent studies and joint analyses with adult cooperative groups.

Treatment Approach — Partial Overview

For localized disease, the approach centers on surgical resection where feasible, followed by adjuvant therapy selected according to individual risk stratification based on tumor stage, site, and size. Adjuvant management may include combination chemotherapy and radiotherapy; in certain fully resected cases, a more limited approach may be appropriate. The complete risk-stratified decision algorithm and regimen specifications are in the full protocol.

Full details — including eligibility criteria, sequencing, and dosing — are available via the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.esmoop.2023.101618

The optimal approach to the treatment of SS in pediatric patients is now better defined.
The disease is rare in the pediatric population, making it difficult to conduct randomized pediatric SS-specific clinical trials.
In localized SS, this typically involves initial first-line resection, where feasible, plus adjuvant or second-line treatments, including a combination of full-dose doxorubicin and ifosfamide chemotherapy, depending on an individual risk stratification that takes account of tumor stage, site, and size.
A prospective trial by the EpSSG in patients <21 years of age with nonmetastatic SS showed that with multimodal treatment, which included radiotherapy and a combination of doxorubicin and ifosfamide chemotherapy according to tumor stage, site, and size, 5-year EFS was 80.7% and OS was 90.7%.
A joint analysis by the EpSSG and the Children's Oncology Group (COG), however, found that pediatric patients with a localized nonmetastatic SS tumor of grade 2 of any size or grades 3 and 5 cm that had been fully resected could be treated effectively with surgery alone.

View source ↗